DK2137202T3 - Fremgangsmåde til syntese af ib-meca - Google Patents
Fremgangsmåde til syntese af ib-meca Download PDFInfo
- Publication number
- DK2137202T3 DK2137202T3 DK08719985.7T DK08719985T DK2137202T3 DK 2137202 T3 DK2137202 T3 DK 2137202T3 DK 08719985 T DK08719985 T DK 08719985T DK 2137202 T3 DK2137202 T3 DK 2137202T3
- Authority
- DK
- Denmark
- Prior art keywords
- meca
- vol
- formula
- diol
- acetonide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Claims (12)
- FREMGANGSMÅDE TIL SYNTESE AF IB-MECA1. Fremgangsmåde til den kemiske syntese af IB-MECA med følgende formel (I):(I) hvilken fremgangsmåde omfatter: (i) omsætning af 6-halopurin-9-ribosid med følgende formel (II):hvor X er et halogen, der er udvalgt fra gruppen bestående af Cl, I og Br; med et diolbeskyttende reagens for at opnå et diolbeskyttet 6-halopurin med følgende formel (III):(ITT) hvor det diolbeskyttende reagens omfatter en lige eller forgrenet CrC6-alkylgruppe; (ii) oxidering af den primære alkohol i det diolbeskyttede 6-halopurin med formlen (III) ved tilsætning af en katalytisk mængde af et oxideringsmiddel bestående af natriumperiodat og rutheniumtrichlorid (RuCl3) for at opnå et tilsvarende carboxylsyrederivat med formlen (IV):(TV) isolering af derivatet ved krystallisering fra vand/acetonitril; (iii) omsætning af carboxylsyregruppcn af derivatet med formlen (IV) med et halogcncringsmiddd SOCl2 i acetonitril for at opnå et syrechlorid efterfulgt af omsætning med methylamin i nærvær af diisopropyletfrylamin (DIPEA) for at opnå det tilsvarende methylamidderivat af det diolbeskyttede 6-halopurin (III), hvor methylamidderivatet har formlen (V):(V) substitution af halogengruppen af methylamidderivat (V) med 3-iodbenzylamin med < 0,5 % af 3-brombenzylaminhydrochlorid, i nærvær af DIPEA, reaktionsblandingen opvarmes til 70 °C. (iv) for at danne en diolbeskyttet IB-MECA med formlen (VI);(VI) og for at muliggøre, at den diolbeskyttede IB-MECA med formlen (VI) rekrystalliserer i en MeOH; (v) fjernelse af diolbcskyttclsc i nærvær af vandig saltsyre for at opnå IB-MECA med formlen (I) ved et renhedsniveau på 99,67 % og 90 % udbytte.
- 2. Fremgangsmåde ifølge krav 1, hvor halogenet er chlorid.
- 3. Fremgangsmåde ifølge krav 1 eller 2, hvor beskyttelsesgruppen er C3-C6-dialkyloxyalkan.
- 4. Fremgangsmåde ifølge krav 3, hvor dialkyloxyalkanen er 2,2-dimethoxypropan.
- 5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor diolbeskyttelsen opnås i nærvær af en kraftig syre og et polært organisk opløsningsmiddel.
- 6. Fremgangsmåde ifølge krav 5, hvor den kraftige syre er udvalgt fra p-TsOH, methansulfonsyre, benzensulfonsyre, myresyre, saltsyre, svovlsyre.
- 7. Fremgangsmåde ifølge krav 5, hvor det polære organiske opløsningsmiddel er et vandblandbart opløsningsmiddel.
- 8. Fremgangsmåde ifølge krav 7, hvor det polære organiske opløsningsmiddel er acetone.
- 9. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 8, hvor oxideringen sker i nærvær af en katalytisk mængde af en blanding af RuC13 og natriumperiodat.
- 10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor 3-iodbenzylaminhydrochloridet tilvejebringes efter rekrystallisering fra et protisk opløsningsmiddel.
- 11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 10, hvor fjernelsen af diolbeskyttelsesgruppen sker i nærvær af en kraftig syre og et polært, ikke-protisk opløsningsmiddel.
- 12. Fremgangsmåde ifølge krav 11, hvor den kraftige syre er HC1 og opløsningsmidlet er tetrahydrofuran (THF).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90683807P | 2007-03-14 | 2007-03-14 | |
PCT/IL2008/000360 WO2008111082A1 (en) | 2007-03-14 | 2008-03-13 | Process for the synthesis of ib-meca |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2137202T3 true DK2137202T3 (da) | 2017-10-02 |
Family
ID=39530638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08719985.7T DK2137202T3 (da) | 2007-03-14 | 2008-03-13 | Fremgangsmåde til syntese af ib-meca |
Country Status (10)
Country | Link |
---|---|
US (1) | US9102698B2 (da) |
EP (1) | EP2137202B1 (da) |
JP (1) | JP5467872B2 (da) |
CN (1) | CN101646685B (da) |
DK (1) | DK2137202T3 (da) |
ES (1) | ES2641190T3 (da) |
HU (1) | HUE034474T2 (da) |
PL (1) | PL2137202T3 (da) |
PT (1) | PT2137202T (da) |
WO (1) | WO2008111082A1 (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019105388A1 (zh) * | 2017-11-29 | 2019-06-06 | 苏州科睿思制药有限公司 | 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途 |
CN110003211A (zh) * | 2019-05-06 | 2019-07-12 | 江苏联昇化学有限公司 | 一种抗癌药物cf-102的合成新工艺 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4930392A (da) | 1972-07-18 | 1974-03-18 | ||
DE2244328A1 (de) | 1972-09-09 | 1974-03-21 | Boehringer Mannheim Gmbh | Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben |
DE69428536T2 (de) * | 1993-07-13 | 2002-06-06 | Nasa | A3 -adenosin -rezeptor agonisten |
IL127947A0 (en) | 1999-01-07 | 1999-11-30 | Can Fite Technologies Ltd | Pharmaceutical use of adenosine agonists |
ATE292973T1 (de) | 2001-01-16 | 2005-04-15 | Can Fite Biopharma Ltd | Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation |
AU2003274648A1 (en) | 2002-10-22 | 2004-05-13 | Can-Fite Biopharma Ltd. | The use of the a3 adenosine receptor as a marker for a diseased state |
AU2003282359A1 (en) | 2002-11-19 | 2004-06-15 | Can-Fite Biopharma Ltd. | A3ar agonists for the treatment of inflammatory arthritis |
CA2513545A1 (en) * | 2003-01-17 | 2004-08-05 | Ajinomoto Co., Inc. | Processes for production of nucleosides |
FI115172B (fi) | 2003-07-24 | 2005-03-15 | Filtronic Lk Oy | Antennijärjestely ulkoisen laitteen liittämiseksi radiolaitteeseen |
EP1699459B1 (en) | 2003-12-29 | 2007-06-06 | Can-Fite Biopharma Ltd. | Method for treatment of multiple sclerosis |
EP1778239B1 (en) | 2004-07-28 | 2013-08-21 | Can-Fite Biopharma Ltd. | Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome |
US7825102B2 (en) * | 2004-07-28 | 2010-11-02 | Can-Fite Biopharma Ltd. | Treatment of dry eye conditions |
KR20070085839A (ko) | 2004-11-08 | 2007-08-27 | 캔-파이트 바이오파마 리미티드 | 가속 골 흡수의 치료 방법 |
MX2007006500A (es) | 2004-12-02 | 2007-07-13 | Can Fite Biopharma Ltd | Tratamiento de inflamacion. |
US20080300213A1 (en) | 2005-11-30 | 2008-12-04 | Pnina Fishman | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment |
JP5185139B2 (ja) | 2006-01-27 | 2013-04-17 | キャン−ファイト・バイオファーマ・リミテッド | ドライアイ疾患治療用アデノシンa3レセプターアゴニスト |
-
2008
- 2008-03-13 CN CN200880007952.9A patent/CN101646685B/zh active Active
- 2008-03-13 PL PL08719985T patent/PL2137202T3/pl unknown
- 2008-03-13 PT PT87199857T patent/PT2137202T/pt unknown
- 2008-03-13 HU HUE08719985A patent/HUE034474T2/en unknown
- 2008-03-13 WO PCT/IL2008/000360 patent/WO2008111082A1/en active Application Filing
- 2008-03-13 ES ES08719985.7T patent/ES2641190T3/es active Active
- 2008-03-13 US US12/450,094 patent/US9102698B2/en active Active
- 2008-03-13 JP JP2009553282A patent/JP5467872B2/ja active Active
- 2008-03-13 EP EP08719985.7A patent/EP2137202B1/en active Active
- 2008-03-13 DK DK08719985.7T patent/DK2137202T3/da active
Also Published As
Publication number | Publication date |
---|---|
ES2641190T3 (es) | 2017-11-08 |
US20100087636A1 (en) | 2010-04-08 |
PL2137202T3 (pl) | 2017-12-29 |
PT2137202T (pt) | 2017-10-02 |
EP2137202B1 (en) | 2017-06-21 |
US9102698B2 (en) | 2015-08-11 |
JP5467872B2 (ja) | 2014-04-09 |
CN101646685B (zh) | 2014-12-17 |
CN101646685A (zh) | 2010-02-10 |
WO2008111082A1 (en) | 2008-09-18 |
EP2137202A1 (en) | 2009-12-30 |
HUE034474T2 (en) | 2018-02-28 |
JP2010521452A (ja) | 2010-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102532498B1 (ko) | 젬시타빈-포스페이트 부분입체이성질체의 분리 방법 | |
EP3150600A1 (en) | Dihydropyrimido loop derivative as hbv inhibitor | |
EP4289823A1 (en) | Substituted pyridazine phenol derivatives | |
JPH0637394B2 (ja) | 腫瘍治療剤 | |
JPH0723394B2 (ja) | 新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 | |
US7371737B2 (en) | 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity | |
EP2341772B1 (en) | Synthesis of decitabine | |
DK2137202T3 (da) | Fremgangsmåde til syntese af ib-meca | |
JP2009541436A (ja) | 治療用化合物 | |
KR20070073958A (ko) | 디플루오로뉴클레오시드 및 이의 제조 방법 | |
JP2023011699A (ja) | 3位置換5-アミノ-6H-チアゾロ[4,5-d]ピリミジン-2,7-ジオン化合物の製造法 | |
EP0749969A2 (en) | d4T polymorphic form I process | |
US7671191B2 (en) | Methods for preparing 2-alkynyladenosine derivatives | |
WO1992019638A1 (fr) | DERIVE DE 1-β-D-ARABINOFURANOSYL-(E)-5-(2-HALOGENOVINYL)-URACILE | |
CN113004202B (zh) | 一种高纯度托伐普坦的制备方法 | |
WO2022124410A1 (ja) | シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法 | |
JP2009541437A (ja) | 治療用化合物 | |
JP2004502780A (ja) | アデノシン化合物及びそれを含む医薬組成物 | |
Lerner | Preparation of the E and Z isomers of 9-(5, 6-dideoxy-. beta.-D-erythro-hex-4-enofuranosyl) adenine | |
JP3025541B2 (ja) | 2−置換アデノシン誘導体および循環器疾患用薬 | |
CN112521405A (zh) | 一种培美曲塞二钠杂质化合物 | |
JP5616355B2 (ja) | モルフィン−6−グルクロニドの2環式誘導体、この調製方法および治療法でのこの使用 | |
JP2509140B2 (ja) | アデノシン誘導体を有効成分として含有する医薬組成物 | |
EP2891660A1 (en) | Process for the preparation of cladribine | |
JPS62240622A (ja) | 抗腫瘍剤 |